Protective role of naringenin against doxorubicin-induced cardiotoxicity in a rat model: Histopathology and mRNA expression profile studies

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 33, Issue 4, 2014, Pages 363-376

  Subburaman, Swathika ^a   Ganesan, Kumaresan ^a   Ramachandran, Murugesan ^a,b  

^a MADURAI KAMARAJ UNIVERSITY   (India)

^b CHETTINAD HOSPITAL AND RESEARCH INSTITUTE   (India)

Author keywords

Antioxidants; Doxorubicin; Inflammation; Lipid peroxidation; mRNA; Naringenin; Transforming growth factor; Tumor necrosis factor

Indexed keywords

BIOCHEMICAL MARKER; DOXORUBICIN; INTERLEUKIN 10; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MALONALDEHYDE; MESSENGER RNA; NARINGENIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; BIOLOGICAL MARKER; FLAVANONE DERIVATIVE; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; ENZYME ACTIVITY; HEART FUNCTION; HEART INJURY; HEART PROTECTION; HISTOPATHOLOGY; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEART; HEART DISEASES; HEART MUSCLE; METABOLISM; PATHOLOGY; TOXICITY; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; DOXORUBICIN; FLAVANONES; GENE EXPRESSION REGULATION; HEART; HEART DISEASES; MALE; MYOCARDIUM; RATS; RATS, WISTAR; RNA, MESSENGER; TRANSCRIPTOME;

EID: 84907974008     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.2014010625     Document Type: Article

References (45)

1. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997;54:1-7.
2. Ewens A, Luo L, Berleth E, Alderfer J, Wollman R, Hafeez BB, Kanter P, Mihich E, Ehrke MJ. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Res. 2006;66:5419-26.
3. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999;57:727-741.
4. Kik K, Studzian K, Wąsowska-Łukawska M, Oszczapowicz I, Szmigiero L. Cytotoxicity and inhibitory properties against topoisomerase II of doxorubicin and its formamidine derivatives. Acta Biochim Pol. 2009;56:135-42.
5. Karagiannis TC, Lin AJ, Ververis K, Chang L, Tang MM, Okabe J, El-Osta A. Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes. Aging. 2010;2:659-68.
6. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229.
7. Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int. J. Nanomed. 2007;2:567-83.
8. Bjelogrlic SK, Radic J, Radulovic S, Jokanovic M, Jovic V. Effects of dexrazoxane and amifostine on evolution of doxorubicin cardiomyopathy in vivo. Exp Biol Med. 2007; 232:1414-24.
9. Julicher RH, Sterrenberg L, Haenen GR, Bast A, Noordhoek J. The effect of chronic adriamycin treatment on heart kidney and liver tissue of male and female rat. Arch Toxicol. 1988;61:275-81.
10. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 2012;18:1639-42.
11. Zhang YC, Tang Y, Zhang M, Chen J, Zhou Q, Sun YG, Chen MT, Xu WP. Fosinopril attenuates the doxorubicin-induced cardiomyopathy by restoring the function of sarcoplasmic reticulum. Cell Biochem Biophys. 2012;64:205-11.
12. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52:1213-25.
13. Salvatorelli E, Menna P, Lusini M, Covino E, Minotti G. Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart. J Pharmacol Exp Ther. 2009;329:175-84.
14. Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21:440-6.
15. Suntres ZE. Liposomal antioxidants for protection against oxidant-induced damage. J Toxicol. 2011;2011:152474-89.
16. Quiles JL, Huertas JR, Battino M, Mataix J, Ramerez-Tortosa MC. Antioxidant nutrients and adriamycin toxicity. Toxicology. 2002;180:79-95.
17. Woodley-Cook J, Shin LY, Swystun L, Caruso S, Beaudin S, Liaw PC. Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway. Mol. Cancer Ther. 2006;5:3303-11.
18. Saalu LC, Ajayi GO, Adeneye AA, Imosemi IO, Osinubi AA. Ethanolic seed extract of grape fruit (Citrus paradisi Macfad) as an effective attenuator of doxorubicin-induced oxidative stress in the rat heart. Int J Cancer Res. 2009;5:44-52.
19. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006;69:213-7.
20. Mercuro G, Cadeddu C, Piras A, Dessì M, Madeddu C, Deidda M, Serpe R, Massa E, Mantovani G. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist. 2007;12:1124-33.
21. Sari FR, Arozal W, Watanabe K, Harima M, Veeravedu PT, Thandavarayan RA, Suzuki K, Arumugam S, Soetikno V, Kodama M. Carvedilol attenuates inflammatory-mediated cardiotoxicity in daunorubicin-induced rats. Pharmaceuticals. 2011;4:551-66.
22. Wang B, Hao J, Jones SC, Yee MS, Roth JC, Dixon IMC. Decreased Smad 7 expression contributes to cardiac fibrosis in the infarcted rat heart. Am. J Physiol. Heart Circ. Physiol. 2002;282:H1685-H1696.
23. Kawano H, Do YS, Kawano Y, Starnes V, Barr M, Law RE, Hsueh WA. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000;101:1130-7.
24. La Vecchia C, Tavani A. Fruit and vegetables, and human cancer. Eur. J Cancer Prev. 1998;7:3-8.
25. Scalbert A, Manach C, Morand C, Remesy C, Jimenez L. Dietary polyphenols and the prevention of diseases. Crit. Rev. Food Sci. Nutr. 2005;45:287-306.
26. Borek C. Dietary antioxidants and human cancer. Integr. Cancer Ther. 2004;3:333-41.
27. Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA. Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr.2001;74:418-25.
28. Shimizu T, Lin F, Hasegawa M, Okada K, Nojiri H, Yamane H. Purification and identification of naringenin 7-O-methyltransferase, a key enzyme in biosynthesis of flavonoid phytoalexin sakuranetin in rice. J. Biol. Chem. 2012;287:19315-25.
29. Ozmen O. Cardiotoxicity and apoptotic activity in subacute endosulfan toxicity and the protective effect of vitamin C in rabbits: a pathological study. J Environ Pathol Toxicol Oncol. 2013;32:53-58.
30. Bast A, Kaiserová H, den Hartog GJ, Haenen GR, van der Vijgh WJ. Protectors against doxorubicin-induced cardiotoxicity: flavonoids. Cell Biol Toxicol. 2007;23:39-47.
31. Liu RH. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr. 2004;134:3479S-3485S.
32. Leonardi T, Vanamala J, Taddeo SS, Davidson LA, Murphy ME, Patil BS, Wang N, Carroll RJ, Chapkin RS, Lupton JR, Turner ND. Apigenin and naringenin suppress colon carcinogenesis through the aberrant crypt stage in azoxymethane-treated rats. Exp Biol Med. 2010;235:710-17.
33. Qin L, Jin L, Lu L, Lu X, Zhang C, Zhang F, Liang W. Naringenin reduces lung metastasis in a breast cancer resection model. Protein Cell. 2011;2:507-16.
34. Erlund I. Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr Res. 2004;24:851-74.
35. Lv Y, Zhang B, Xing G, Wang F, Hu Z. Protective effect of naringenin against acetaminophen-induced acute liver injury in metallothionein (MT)-null mice. Food Funct. 2013;4:297-302.
36. Moretti E, Mazzi L, Terzuoli G, Bonechi C, Iacoponi F, Martini S, Rossi C, Collodel G. Effect of quercetin, rutin, naringenin and epicatechin on lipid peroxidation induced in human sperm. Reprod Toxicol. 2012;34:651-7.
37. Badary OA, Maksoud SA, Ahmed WA, Owieda GH. Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sci. 2005;76:2125-35.
38. Fadillioglu E, Erdogan H. Effects of erdosteine treatment against doxorubicin-induced toxicity through erythrocyte and plasma oxidant/antioxidant status in rats. Pharmacol Res. 2003;47:317-22.
39. Singal PK, Iliskovic N. Adriamycin cardiomyopathy. N Engl J Med. 1998;339:900-05.
40. Xu MF, Tang PL, Qian ZM, Ashraf M. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci. 2001;68:889-901.
41. Chularojmontri L, Wattanapitayakul SK, Herunsalee A, Charuchongkolwongse S, Niumsakul S, Srichairat S. Antioxidative and cardioprotective effects of Phyllanthus urinaria L. on doxorubicin-induced cardiotoxicity. Biol Pharm Bull. 2005;28:1165-71.
42. Han XZ, Gao S, Cheng YN, Sun YZ, Liu W, Tang LL, Ren DM. Protective effect of naringenin-7-O-glucoside against oxidative stress induced by doxorubicin in H9c2 cardiomyocytes. BiosciTrends. 2012;6:19-25.
43. Totta P, Acconcia F, Leone S, Cardillo I, Marino M. Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor alpha and beta signalling. IUBMB Life. 2004;56:491-9.
44. Li T, Danelisen I, Belló-Klein A, Singal PK. Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc Res. 2000; 46: 523-30.
45. Bien S, Riad A, Ritter CA, Gratz M, Olshausen F, Westermann D, Grube M, Krieg T, Ciecholewski S, Felix SB, Staudt A, Schultheiss HP, Ewert R, Völker U, Tschöpe C, Kroemer HK. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res. 2007;67:10428-35.